 | |
| Clinical data | |
|---|---|
| Trade names | Nourianz, Nouryant[1] |
| Other names | KW-6002 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth |
| Drug class | Adenosine A2A receptor antagonist[2] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 98% |
| Metabolism | Mainly CYP1A1, CYP3A4, and CYP3A5 |
| Elimination half-life | 64–69 hrs |
| Excretion | 68% faeces, 18% urine |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C20H24N4O4 |
| Molar mass | 384.436 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Istradefylline, sold under the brand name Nourianz, is a medication used with levodopa/carbidopa for "off" episodes in Parkinson's disease (PD).[4][6] An "off" episode is a time when other medications are not working well, resulting in tremor and difficulty walking.[4] It is taken by mouth.[4]
Common side effects include involuntary muscle movements, constipation, hallucinations, dizziness, nausea, and trouble sleeping.[4] Other side effects may include compulsive behavior.[4] It is a adenosine A2A receptor antagonist.[2]
Istradefylline was approved for medical use in the United States in 2019.[5] In Europe it was refused approval in 2021 due to unclear evidence of benefit.[2] It is not available in the United Kingdom.[1] In the United States it costs about 1,500 USD per month.[7]
References
edit- ^ a b "Istradefylline". SPS - Specialist Pharmacy Service. 18 September 2019. Archived from the original on 24 May 2021. Retrieved 1 December 2021.
- ^ a b c "Nouryant". Archived from the original on 14 November 2021. Retrieved 1 December 2021.
- ^ "Nourianz- istradefylline tablet, film coated". DailyMed. Archived from the original on 2 November 2021. Retrieved 4 January 2021.
- ^ a b c d e f g "Drug Trials Snapshots: Nourianz". U.S. Food and Drug Administration (FDA). 23 September 2019. Archived from the original on 20 November 2019. Retrieved 19 November 2019.
This article incorporates text from this source, which is in the public domain.
- ^ a b "Istradefylline Monograph for Professionals". Drugs.com. Archived from the original on 18 October 2019. Retrieved 26 November 2021.
- ^ Cabreira V, Soares-da-Silva P, Massano J (April 2019). "Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review". Drugs. 79 (6): 593–608. doi:10.1007/s40265-019-01098-w. PMID 30905034. S2CID 85456263.
- ^ "Istradefylline Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 1 December 2021.
